IDEAYA Biosciences Announces ESMO 2026 Presentations for Darovasertib and IDE849 Clinical Programs
July 17, 2026
IDEAYA Biosciences, Inc. Reports Second Quarter 2021 Financial Results and Provides Business Update
August 10, 2021
Related Post
-
-
Plus Therapeutics and Genomic Testing Cooperative Partner to Integrate Next-Generation Sequencing Into the CNSide® CSF Assay Platform
July 16, 2026
-
XOMA Royalty Announces Closing of Its Acquisition by Ligand
July 14, 2026
-
Oncolytics Biotech® Reports FDA Regulatory Milestone and Strong Clinical Progress in Randomized RAS-Mutant MSS Colorectal Cancer Trial
July 13, 2026